Re: Dr. Blais on Platinum

[Guest guest]

Bless Dr. Blais for all that he has done for us. He was part of the plan to

make sure that we are all vindicated. We thank him and we love him...Lea

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~````

Dr. Blais on Platinum

> Thanks Lea,

> =========================

>

> Ilena,

>

> Hope this will help on the platinum issue. I have

> gone by Blais when I claim that the platinum in our

> implants is like the Platinol. Hope there is no legal

> reason to NOT post it. It has circulated for years.

> Think the women will find it interesting.

>

> Dr Pierre Blais is an expert on implants and has been

> correct in all of his predications and observations.

> He has 21 years of implant experience. Let's let him

> explain about the PLATINUM in our implants.

> Chlorplatinic acid. This information on platinum was

> taken from a deposition given by Pierre Blais in 1993.

>

> This portion begins at a discussion regarding the

> leaching and leakage of the implant content back into

> the patient, and the term 'bleed,' not just as the

> leakage of silicone oil. There are some unessential

> comments omitted and indicated by (..................)

>

> Blais: It has to be now perceived as leakage of oil

> plus a chemically reactive, pharmacologically active

> entity, a catalyst.

>

> Attorney: When was the first time that you recall

> testifying that a catalyst was now something that had

> to be considered in connection with this issue,

> silicone issue?.......

>

> Blais: The issue of the collectivity of substances

> that effuse, diffuse, and somehow permeate and are

> released to the patient incidental to its dwell time

> was broached in virtually every deposition I've ever

> given on this topic. ...............

>

> However, the one that raised the issue and developed

> it to the greatest degree up to now is the deposition

> of versus Baxter HealthCare, and that goes back

> almost two years. {approx 1991}

>

> Att: Now, insofar as the effusion, diffusion, and I

> think you used the term osmosis to group the types of

> action that have been improperly characterized as

> bleed heretofore -- am I correct on that:

>

> Blais: Correct

>

> Att: Are you simply raising that to say that when you

> have this effusion, diffusion, or osmosis not only

> will it involve silicone, but it might involve this

> PLATINUM?

>

> Blais: As well as many other things.

>

> Att: We are just talking about those two now.

>

> Blais: For the sake of this discussion, given that

> the catalyst forma a measurable and calculable part of

> the mobile component, the oil, then it follows that

> the oil will entrain this catalyst in a proportional

> way: therefore, making this oil a solution, not an

> oil.

>

> Att: You mean that's because the catalyst is in

> solution in the oil?

>

> Blais: Correct. It's dispersed, distributed somehow,

> made available through an oil vehicle.

>

> Att: It's actually in solution, you're saying?

>

> Blais: A part of it is in solution, part of it is

> there as an aggega, a molecule, a larger molecule; but

> as I may have -- as I have mentioned to you before, I

> believe in the closing of the last deposition, bleed

> is an incorrect term. It's actually leakage through

> holes, and if it moves, it gets out.

>

> Att: Now, just to complete the picture so that I

> understand it, assuming some amount gets out, there is

> something called trace amounts known in this area of

> science we are discussing.

>

> Blais: Well, the term 'trace' is not descriptive.

>

> Att: Just define trace as it is generally used, if

> you can. If not, fine.

>

> Blais: I've never, ever used that term in any of my

> publications. The spirit of trace means very small,

> parasitic amounts that are of no consequence. I do not

> agree with the term for that reason.

>

> Att: Well, let's just not use the term, then, if you

> don't want -- like or agree with it. Let me just ask

> you this: There are certain measurements of quantities

> of amounts, correct?

>

> Blais: That is correct.

>

> Att: As you've explained it to me with such patience

> today, the quantities may be different or vary from

> implant to implant, manufacturer to manufacturer,

> batch to batch, correct?

>

> Blais: Yes.

>

> Att: We are talking about the quantities in this

> particular case of the catalyst?

>

> Blais: Correct.

>

> Att: So that measurements done even in this protocol

> of this study that you are talking about, where they

> are measuring catalysts that may be involved in

> certain patients, as against normal controls, or

> unexposed controls, it might tell you what's involved

> in that situation, but it might not equate to some

> other manufacturer or some other implant because of

> the difference in quantities, correct?

>

> Blais: Correct.

>

> Att: Then as I understand the procedure, it would

> then be to at some point determine whether the amount,

> let's say there is an amount shown in this Houston

> study just for the sake of argument, the amount of

> catalyst shown is responsible for any clinical

> symptomology or damage? That would be the next step?

>

> Blais: Well that relates more to clinical causation,

> and there we may reenter into published literature.

>

> Att: When you say you may reenter into published

> literature, you may look at literature that's already

> published?

>

> Blais: Correct.

>

> Att: You may also, if that doesn't give you an

> answer, you may have to design a study to test that

> property.

>

> Blais: That is possible; but it is a strange time to

> initiate such a study.

>

> Att: You may not want to do it now, but I'm just

> saying it may not be answerable without a study, if

> it's not answerable by literature, depending upon

> what, of course, is determined by the initial

> study...............(lawyer dialogue)........... Are

> you answering whether a study might be necessary, or

> are you saying something else, now? You can tell me

> that.

>

> Blais: I'm saying at the point where such a study

> could be designed, there is already a body of

> literature dealing with the causation of

> organoplatinates in terms of neurologic symptoms, and

> in fact it's very, very common literature.

>

> Att: All right, fine.

>

> Blais: And if, perhaps to round out the deposition,

> we could file an exhibit to that effect ---

>

> Att: Well, that's certainly something that you might

> very well consider. I would have no objection to you

> doing that, and it might be very helpful. You have

> that information with you? You're saying to round out

> the deposition right now?

>

> Blais: Right. You can file an exhibit that would make

> life somewhat easier, and it would probably circumvent

> a lot of discussion. What I have here is an extract

> from the Physician Desk Reference, the PRD, which is

> one of the most common publications in the

> medico-pharmacological area, and in one of its

> subheadings under the Bristol-Meyers oncology product,

> I have a compound registered as PLATINOL, also known

> as CISPLATIN, referenced through my Exhibit 1, and it

> describes one of those compounds, the most water

> soluble version of it, as being very well known and

> very well characterized in terms of medical and

> neurological side effects.

>

> Att: Well, thank you so much . I appreciate that.

> (discussion on marking Exhibit 8)......

>

> Blais: If it assists you (meaning the defense

> attorney) I can use the last minute of the deposition

> or whatever time you wish to locate, to bridge the

> exhibits, therefore forming a closed and coherent

> circle.

>

> Att: I'll allow you to do that, but I want to ask one

> question before that. Other than Defendants', are you

> aware of any other literature on this particular

> issue, that is, the issue of the potential or the

> actual causing of any injuries or other problems by

> what you have termed 'Cisplatinum?' [sic] (Cisplatin)

>

> Blais: There is a comparatively large body of

> literature on the pharmacology and adverse reactions

> surrounding the use of platinates. I have not brought

> this file with me. My own file is not complete, but it

> is substantial.

>

> Att: Now, you were going to tie Exhibit 8 to Exhibit

> 1.

>

> Blais: Correct. In Exhibit 1, the compound which is

> shown on the extreme left hand, what is labeled in my

> exhibit as Cisplatin, trademark, as in Exhibit 8,

> right in the first paragraph, whereas the trade name

> for it is Platinol..

>

> Att: I see it as saying this is H3N, and you have

> H2N.

>

> Blais: Well, no, the molecule is the same. It's a

> diamino. There might be a misprint there.

>

> Att: Misprint where:

>

> Blais: In the PDR.

>

> Defense: The PDR has a misprint?

>

> Blais: It should be a diamino if the printing is

> correct. It does show a 3.

>

> Actually, no. It's correct if we take into

> consideration that that molecule is also incomplete.

> It is hydrated. What has happened, they have shown the

> third hydrogen borrowed from the hydrated molecule,

> whereas here I've shown it as simply a balanced core.

>

> Att: I wanted to point out that it wasn't exactly the

> same, as opposed to what you have said..........but

> you can still bring it to a circle.

>

> Blais: Basically, I've drawn the same molecule using

> a different convention. The items -- the item was

> introduced in the first place in Exhibit 1 because it

> forms part of the discussion, and it links back to the

> earlier days when people were seeking antitumor

> agents, and it was found that the choloroplatinates in

> general had antitumor activity. They were basically

> alkylating agents: whereas they could cause cancer,

> they could also cure it. So there was a lot of initial

> work and initial fervor in using it for resolution of

> progressive tumors of the prostate and the ovarian

> area.

>

> However, during the discovery, much of which is

> credible to Bristol- Meyers researchers, they very

> quickly established that the members of this family,

> which were lipid-liking lipophilics, were also

> extremely neurotoxic and they were rejected on the

> first round. Instead, they chose to make the molecule

> more water-liking by making it instead a diamino,

> instead of an alkyl or disilyl, therefore, EXPLAINING

> WHY THE CATALYST USED FOR SILICONES IS NOT A GOOD

> PHARMACEUTICAL BECAUSE IT IS TOO NEUROTOXIC, and

> EXPLAINS CONVERSELY WHY THE DRUG CISPLATIN OR PLATINOL

> IS NOT A GOOD CATALYST FOR MAKING PROSTHESES, because

> it is water soluable, and in our case we wish to have

> an oil soluable entity, and that is where we sit at

> the moment.

>

>

>

>

> Opinions expressed are NOT meant to take the place of advice given by

> licensed health care professionals. Consult your physician or licensed

> health care professional before commencing any medical treatment.

>

> " Do not let either the medical authorities or the politicians mislead you.

> Find out what the facts are, and make your own decisions about how to live

> a happy life and how to work for a better world. " - Linus ing,

> two-time Nobel Prize Winner (1954, Chemistry; 1963, Peace)

>

>